Gorav Jindal is a skilled antitrust lawyer with superior knowledge of agency practice, procedure and personnel. He combines the quantitative analysis of a background in engineering and economics with the persuasive skills of a litigator and nationally ranked inter-collegiate debater. He guides clients past antitrust obstacles, providing innovative antitrust analyses to clients, whether in defense of a potential or consummated transaction or as a counselor on the full range of business practices.
Practice and Background
Mr. Jindal’s practice combines government and private sector experience on behalf of clients in a variety of industries, including pharmaceuticals, energy, health care and life sciences, chemicals, technology, airlines, food and agriculture, construction, online recruiting, supermarkets, travel management, global distribution services and intellectual property. He handles all phases of merger investigations conducted by the U.S. Department of Justice (DOJ) and the Federal Trade Commission (FTC). He has navigated clients through the antitrust aspects of transformative transactions and antitrust litigation, and was a key member of the team that won Global Competition Review’s antitrust “Matter of the Year” award in 2014.
Of particular focus in Mr. Jindal’s practice is the pharmaceutical industry. He has represented both large and small pharmaceutical companies under investigation by the FTC for price-fixing, improperly listing patents in the Orange Book, entering into illegal patent settlements and allegations of business practices designed to unfairly lengthen the lifecycle of branded drugs under the Hatch-Waxman Act.The 2017 Legal 500 noted his “particular expertise in antitrust issues connected with the pharmaceuticals sector,” recognizing him as a Recommended Lawyer for Antitrust-Merger Control.
Mr. Jindal also has experience handling antitrust litigation matters. He has assisted in the development of litigation strategy for preliminary injunction hearings and complex commercial litigation. He also represents clients that have been targeted in criminal antitrust proceedings, focusing on the plausibility of criminal theories and assessing the likelihood of indictments and convictions.
Prior to joining private practice, Mr. Jindal served in the FTC’s Bureau of Competition. There, he investigated a number of highly publicized transactions, including mergers in the publishing, computer hardware and chemical industries, and was responsible for interviewing and securing testimony, deposing witnesses, preparing expert testimony, assisting in drafting recommendations to the Bureau’s management and drafting settlements.
Mr. Jindal has served as antitrust counsel to health care, energy, pharmaceutical, airline and supermarket chain clients, assisting them in a variety of strategic transactions and litigation, including high-profile mergers and acquisitions. Some of his recent representations include:
- Representing a network airline carrier in its merger with another network airline carrier
- Securing unconditional clearance for a leading fossil-fuel producer in the sale of certain assets to a nearby rival
- Formulating the antitrust strategy to obtain international clearance in the hostile takeover of a large fossil-fuel producer by a leading global producer in the same industry
- Securing unconditional clearance for a leading integrated pharmaceutical drug pharmacy in its acquisition of the largest specialized nationalized pharmacy in its segment
- Representing a dialysis provider in a sale to a rival
- Representing a diversified pharmaceutical company in the sale of its consumer health products division to a leading global competitor.
- Representing a pharmaceutical company in a $1.9 billion acquisition
- Representing a GDS service provider in a second-phase investigation conducted by the DOJ
- Representing an online recruiting company in an acquisition transaction
- Representing a supermarket chain against the FTC’s efforts to block its acquisition of another supermarket chain
- Representing a domestic dairy processor in its $2.5 billion acquisition.
Mr. Jindal’s presentations include:
- Latest Trends in Merger Enforcement, Driven (June 2016)
- Recent Antitrust Developments in the Health Care and Pharmaceuticals Markets, ABA Section of Antitrust Law Health Care & Pharmaceuticals Committee (May and June 2014).